Report overview
Noninvasive Cancer Diagnostics Technology is a process for the detection of disease through minimal incisions into the body. Noninvasive cancer diagnostic technologies provide fast and convenient procedures for noninvasive early detection of cancer and provide a valuable aid to the clinician and increased comfort to the patient.Noninvasive Cancer Diagnosis Technologies are used to identify breast, lung, blood, and other cancers.
This report contains market size and forecasts of Noninvasive Cancer Diagnostics Technology in Global, including the following market information:
Global Noninvasive Cancer Diagnostics Technology Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Noninvasive Cancer Diagnostics Technology market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Immunoassays Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Noninvasive Cancer Diagnostics Technology include Precision Therapeutics, Affymetrix Inc., Gen-Probe Incorporated, AVIVA Biosciences Corporation, A&G Pharmaceutical, BIOVIEW Inc., Quest Diagnostics Incorporated, Digene Corporation and Laboratory Corporation of America Holdings.. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Noninvasive Cancer Diagnostics Technology companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Noninvasive Cancer Diagnostics Technology Market, by Technology, 2017-2022, 2023-2028 ($ millions)
Global Noninvasive Cancer Diagnostics Technology Market Segment Percentages, by Technology, 2021 (%)
Immunoassays
Molecular Diagnostics
Clinical Chemistry
Others
Global Noninvasive Cancer Diagnostics Technology Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Noninvasive Cancer Diagnostics Technology Market Segment Percentages, by Application, 2021 (%)
Medical Device Manufacturing Company
Oncology Laboratories
Government and Private Research Institutions
Academic Institutions and Pharmaceutical Companies
Others
Global Noninvasive Cancer Diagnostics Technology Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Noninvasive Cancer Diagnostics Technology Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Noninvasive Cancer Diagnostics Technology revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Noninvasive Cancer Diagnostics Technology revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Precision Therapeutics
Affymetrix Inc.
Gen-Probe Incorporated
AVIVA Biosciences Corporation
A&G Pharmaceutical
BIOVIEW Inc.
Quest Diagnostics Incorporated
Digene Corporation
Laboratory Corporation of America Holdings.
